A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.

Nature Biotechnology
Volker SchellenbergerWillem P C Stemmer

Abstract

Increasing the in vivo residence times of protein therapeutics could decrease their dosing frequencies. We show that genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, called XTEN, to a peptide or protein provides an apparently generic approach to extend plasma half-life. Allometric scaling suggests that a fusion of XTEN to the exenatide peptide should increase exenatide half-life in humans from 2.4 h to a projected time of 139 h. We confirmed the biological activity of the exenatide-XTEN fusion in mice. As extended stability might exacerbate undesirable side effects in some cases, we show that truncating the XTEN sequence can regulate plasma half-life. XTEN lacks hydrophobic amino acid residues that often contribute to immunogenicity and complicate manufacture. Based on data on XTEN fusions to exenatide, glucagon, GFP and human growth hormone, we expect that XTEN will enable dosing of otherwise rapidly cleared protein drugs at up to monthly intervals in humans.

References

Nov 1, 1974·American Journal of Obstetrics and Gynecology·R A ChezD L Hutchinson
Jan 1, 1983·International Archives of Allergy and Applied Immunology·A W Richter, E Akerblom
Feb 1, 1995·The Journal of Experimental Medicine·F Sinigaglia, J Hammer
Feb 15, 2001·Current Gastroenterology Reports·M L Shiffman
Jan 11, 2002·European Journal of Biochemistry·Vladimir N Uversky
Mar 4, 2003·Nature Reviews. Drug Discovery·J Milton Harris, Robert B Chess
Nov 13, 2003·The Journal of Biological Chemistry·Paula AlvarezOscar Campetella
Dec 4, 2003·Expert Opinion on Biological Therapy·Gerd Kochendoerfer
Apr 25, 2006·Nature Chemical Biology·Sunil ShaunakSteve Brocchini
Apr 24, 2007·Journal of Pharmaceutical and Biomedical Analysis·Mario CindrićJasna Peter-Katalinić
Nov 13, 2007·Journal of Peptide Science : an Official Publication of the European Peptide Society·Yan-Shan HuangLin-Fu Zhou
Jan 9, 2008·International Journal of Pharmaceutics·Guo AiYuanguo Cheng
Jan 18, 2008·Journal of Pharmaceutical Sciences·C Simone Fishburn
Apr 23, 2008·Expert Opinion on Drug Delivery·Sinéad M RyanDavid J Brayden

❮ Previous
Next ❯

Citations

May 31, 2013·Clinical Pharmacokinetics·Lei Diao, Bernd Meibohm
Sep 26, 2013·Trends in Pharmacological Sciences·Chava Kimchi-SarfatyZuben E Sauna
Jan 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Miriam AmiramAshutosh Chilkoti
May 31, 2013·European Heart Journal Cardiovascular Imaging·Frank M BengelKai C Wollert
Jun 12, 2013·Protein Engineering, Design & Selection : PEDS·Martin SchlapschyArne Skerra
Oct 18, 2013·Protein Engineering, Design & Selection : PEDS·Vladimir N PodustVolker Schellenberger
Jul 24, 2012·Science·Jeffrey A Hubbell, Ashutosh Chilkoti
Sep 17, 2013·Drug Design, Development and Therapy·Yunpeng CaiWeien Yuan
Apr 18, 2014·International Journal of Nanomedicine·Pu ShiJ Andrew MacKay
Sep 20, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jonathan T SockoloskyFrancis C Szoka
Jul 26, 2013·Therapeutic Delivery·Alicia Sawdon, Ching-An Peng
Mar 29, 2014·Protein Engineering, Design & Selection : PEDS·Christian TiedeMichael J McPherson
Apr 1, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Robert LiebnerAhmed Besheer
Oct 3, 2012·Advanced Drug Delivery Reviews·Xiaoying ChenWei-Chiang Shen
Jul 16, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Martha K PastuszkaJ Andrew MacKay
Nov 20, 2014·Future Medicinal Chemistry·Claire GinnSteve Brocchini
Sep 3, 2010·Proceedings of the National Academy of Sciences of the United States of America·Weiping GaoAshutosh Chilkoti
Aug 23, 2011·Expert Opinion on Drug Delivery·Chen ChenMahendra Deonarain
Nov 21, 2015·Expert Opinion on Investigational Drugs·Brian TomlinsonZhong-Min Liu
Nov 20, 2015·Expert Opinion on Emerging Drugs·Magdalena SwierczewskaSeulki Lee
Jun 9, 2012·Journal of Pharmaceutical Sciences·Jeffrey L ClelandVolker Schellenberger
Nov 22, 2012·Protein Expression and Purification·Jonathan T Sockolosky, Francis C Szoka
Oct 18, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Nicolas Bertrand, Jean-Christophe Leroux
Oct 18, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Everett StoneGeorge Georgiou
Oct 27, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vladimir N PodustVolker Schellenberger
Jun 17, 2011·Current Opinion in Biotechnology·Ruth Duncan
Mar 30, 2011·Biotechnology Advances·Anna SzlachcicJacek Otlewski
Dec 7, 2010·Protein Expression and Purification·Erik VernetMichael Sundström
Dec 15, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Caslin A GilroyAshutosh Chilkoti
Sep 12, 2015·Current Opinion in Chemical Biology·Yizhi Qi, Ashutosh Chilkoti
Sep 26, 2015·Biomacromolecules·Erik J LiuShaoyi Jiang
Apr 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Peng-Yu YangWeijun Shen
Nov 19, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jordan DespanieJ Andrew MacKay
Jul 8, 2015·Molecular and Cellular Endocrinology·Brian FinanTimo D Müller
Sep 8, 2015·Nature Chemical Biology·Sravan C PenchalaMamoun M Alhamadsheh
Jul 19, 2015·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Charlotte HøybyeUNKNOWN Growth Hormone Research Society
Jul 17, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·William R Strohl
Aug 10, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·M AmiramA Chilkoti
Aug 25, 2011·Current Opinion in Biotechnology·Roland E Kontermann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nature Reviews. Immunology
Derry C Roopenian, Shreeram Akilesh
Nature Reviews. Drug Discovery
J Milton Harris, Robert B Chess
Nature Biotechnology
Jonathan ZalevskyJohn R Desjarlais
© 2022 Meta ULC. All rights reserved